Arbitration Board Setting Reimbursement Amounts for Pharmaceutical Innovations in Germany When Price Negations between Payers and Manufacturers Fail- An Empirical Analysis of 5 Years’ Experience

Dec 1, 2016, 00:00 AM
10.1016/j.jval.2016.05.016
https://www.valueinhealthjournal.com/article/S1098-3015(16)30507-1/fulltext
Section Title : Health Policy Analysis
Section Order : 3
First Page : 1016

Background

In Germany, an arbitration board is setting reimbursement amounts for drug innovations when price negations between payers and manufacturers fail.

Objective

To empirically analyze all arbitrations since the reform of Germany’s Act to Reorganize the Pharmaceuticals’ Market in the Statutory Health Insurance System came into effect.

Methods

All available relevant documents up to January 2016 were screened and the identified contentious issues between the negotiation parties extracted. Reimbursement requests of both the negotiating parties and the arbitrations were transformed into a comparable format on the basis of defined daily doses and then contrasted among each other.

Results

In the given period, 16 arbitrations took place. The arbitration board is implementing the same criteria used in the negotiations between manufacturers and payers. Almost all arbitrations dealt with generic appropriate comparative therapies. Reimbursement amounts set by arbitration were on average 38.4% less than the mean of negotiation parties’ requests (69.2% less than the manufacturers’ requests). The corresponding prescription volumes were arranged rather centrally. All but one arbitration refer to a 1-year contract period. The arbitration board rarely decided on further technical contentious points. Hence, no heuristics referring to them were derivable.

Conclusions

There is some evidence for a quasi-algorithmic approach of the arbitration board, even though it is legally determined that it has to decide while taking the peculiar conditions of each case into due consideration, including the characteristics of the respective therapeutic area. The balance of interests proved to be within a very narrow space albeit it concerns in principle discretionary decisions. Thus, the purpose of arbitration seems not to be achieved sufficiently.

https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)30507-1&doi=10.1016/j.jval.2016.05.016
HEOR Topics :
  • Health Policy & Regulatory
  • Pricing Policy & Schemes
  • Reimbursement & Access Policy
Tags :
  • AMNOG
  • arbitration board
  • early benefit assessment
  • price negotiations
  • reimbursement amount
Regions :
  • Africa
  • Eastern and Central Europe
  • Middle East
  • Western Europe